Kenvue Inc. $KVUE Shares Sold by Northeast Investment Management

Northeast Investment Management cut its stake in shares of Kenvue Inc. (NYSE:KVUE) by 35.2% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 26,997 shares of the company’s stock after selling 14,666 shares during the quarter. Northeast Investment Management’s holdings in Kenvue were worth $565,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Pittenger & Anderson Inc. acquired a new position in shares of Kenvue during the first quarter worth about $30,000. Trust Co. of Vermont grew its position in shares of Kenvue by 266.8% during the second quarter. Trust Co. of Vermont now owns 1,581 shares of the company’s stock worth $33,000 after buying an additional 1,150 shares in the last quarter. TruNorth Capital Management LLC acquired a new position in shares of Kenvue during the first quarter worth about $36,000. Truvestments Capital LLC acquired a new position in shares of Kenvue during the first quarter worth about $37,000. Finally, Clal Insurance Enterprises Holdings Ltd boosted its holdings in Kenvue by 378.5% in the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 1,627 shares of the company’s stock valued at $39,000 after purchasing an additional 1,287 shares in the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Kenvue Price Performance

Shares of KVUE opened at $15.30 on Monday. Kenvue Inc. has a fifty-two week low of $14.05 and a fifty-two week high of $25.17. The company has a market capitalization of $29.37 billion, a price-to-earnings ratio of 20.68, a price-to-earnings-growth ratio of 2.20 and a beta of 0.72. The firm has a 50-day simple moving average of $18.54 and a 200-day simple moving average of $21.02. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.68 and a current ratio of 0.98.

Kenvue (NYSE:KVUE) last issued its quarterly earnings results on Thursday, August 7th. The company reported $0.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.28 by $0.01. Kenvue had a return on equity of 20.06% and a net margin of 9.37%.The firm had revenue of $3.84 billion for the quarter, compared to analysts’ expectations of $3.94 billion. During the same quarter in the previous year, the firm posted $0.32 EPS. The firm’s revenue for the quarter was down 4.0% on a year-over-year basis. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. On average, equities research analysts anticipate that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, August 27th. Investors of record on Wednesday, August 13th were issued a dividend of $0.2075 per share. This is a boost from Kenvue’s previous quarterly dividend of $0.21. This represents a $0.83 annualized dividend and a dividend yield of 5.4%. The ex-dividend date of this dividend was Wednesday, August 13th. Kenvue’s dividend payout ratio is 112.16%.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the stock. Zacks Research raised shares of Kenvue to a “strong sell” rating in a report on Monday, August 11th. Canaccord Genuity Group dropped their target price on shares of Kenvue from $29.00 to $26.00 and set a “buy” rating on the stock in a research report on Friday, August 8th. Rothschild & Co Redburn upgraded shares of Kenvue from a “neutral” rating to a “buy” rating and cut their price target for the stock from $22.50 to $22.00 in a research note on Friday, September 26th. JPMorgan Chase & Co. reduced their price target on shares of Kenvue from $24.00 to $21.00 and set an “overweight” rating for the company in a research report on Friday, October 10th. Finally, Rothschild Redb raised Kenvue from a “hold” rating to a “strong-buy” rating in a report on Friday, September 26th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $21.18.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.